CR20240417A - Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales estactogénicos - Google Patents

Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales estactogénicos

Info

Publication number
CR20240417A
CR20240417A CR20240417A CR20240417A CR20240417A CR 20240417 A CR20240417 A CR 20240417A CR 20240417 A CR20240417 A CR 20240417A CR 20240417 A CR20240417 A CR 20240417A CR 20240417 A CR20240417 A CR 20240417A
Authority
CR
Costa Rica
Prior art keywords
entactogenic
compositions
mindstates
methods
therapeutic combinations
Prior art date
Application number
CR20240417A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Ray
Original Assignee
Mindstate Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindstate Design Labs Inc filed Critical Mindstate Design Labs Inc
Publication of CR20240417A publication Critical patent/CR20240417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20240417A 2022-03-09 2023-03-09 Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales estactogénicos CR20240417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318369P 2022-03-09 2022-03-09
PCT/US2023/014926 WO2023172701A2 (en) 2022-03-09 2023-03-09 Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates

Publications (1)

Publication Number Publication Date
CR20240417A true CR20240417A (es) 2025-03-04

Family

ID=87935763

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240417A CR20240417A (es) 2022-03-09 2023-03-09 Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales estactogénicos

Country Status (11)

Country Link
US (1) US20250177354A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489649A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509432A (cg-RX-API-DMAC7.html)
KR (1) KR20250011101A (cg-RX-API-DMAC7.html)
CN (1) CN119497589A (cg-RX-API-DMAC7.html)
AU (1) AU2023232712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245622A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240417A (cg-RX-API-DMAC7.html)
IL (1) IL315512A (cg-RX-API-DMAC7.html)
MX (1) MX2024011043A (cg-RX-API-DMAC7.html)
WO (1) WO2023172701A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721978D0 (en) * 1997-10-17 1997-12-17 Lilly Co Eli Treatment of depression
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
US12414936B2 (en) * 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound

Also Published As

Publication number Publication date
WO2023172701A3 (en) 2023-11-09
JP2025509432A (ja) 2025-04-11
US20250177354A1 (en) 2025-06-05
EP4489649A2 (en) 2025-01-15
IL315512A (en) 2024-11-01
WO2023172701A2 (en) 2023-09-14
EP4489649A4 (en) 2026-07-01
MX2024011043A (es) 2024-12-06
KR20250011101A (ko) 2025-01-21
CN119497589A (zh) 2025-02-21
AU2023232712A1 (en) 2024-10-17
CA3245622A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2022009527A (es) Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
ZA202204929B (en) Rimegepant for cgrp related disorders
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
PA8548901A1 (es) Ligandos del receptor 5-ht y sus usos
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
NO20056134L (no) Kombinasjon av en NMDA-reseptorantagonist og en selektiv serotoningjenopptaksinbibitor for behandling av depresjon og andre sinnsstemningsforstyrrelser
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
EP2004188A4 (en) BENZOIMIDAZOLE-2-YL PYRIDINES AS HISTAMINE H4 RECEPTOR MODULATORS
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
CO2019004756A2 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño
MX2024003529A (es) Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica.
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2023172701A3 (en) Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates
DOP2024000165A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases